The sales are routine 10b5-1 plan transactions and do not suggest insider concern about the business. Monitor the next 10-Q for any change in Tyvaso or Orenitram prescription trends, which are the key revenue drivers.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $588.61entry
- T+1 · 6d ago +1.20%α −0.12% · $595.66
- T+4 · todayOpen
- T+5 · in 8h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CEO Martine Rothblatt and EVP Paul Mahon sold a combined $108K in open-market sales under 10b5-1 plans, following the company's Q3 earnings report that showed revenue above consensus but EPS below due to a $130M in-process R&D charge. The sales are small relative to the $24.1B market cap (0.0004%) and appear to be routine plan-driven transactions, not a signal of deteriorating fundamentals.
Key Financial Metrics
Key Facts
- CEO Rothblatt sold $61K in open-market shares on Nov 6 under a 10b5-1 plan
- EVP Mahon sold $47K in open-market shares on Nov 5 under a 10b5-1 plan
- Total insider sales of $108K represent 0.0004% of UTHR's $24.1B market cap
- Sales occurred 1-2 days after Q3 2026 earnings (revenue $832.5M, +4% YoY, above $781.1M consensus; GAAP EPS $5.71 below $6.04 consensus due to $130M IPR&D charge)
- Both sales were under 10b5-1 plans, indicating pre-arranged trading schedules
Financial Impact
Insider sales of $108K total, immaterial relative to $24.1B market cap
Risk Factors
- GAAP EPS missed consensus due to $130M IPR&D charge from Thymmune acquisition
- CEO exercised 9,500 derivative shares at $0 and sold a portion, which is typical for tax and diversification planning
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1794264131457 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Viewing Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers